Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318277 · ClinicalTrials.gov registry record · Phase 1
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
NCT02318277 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 176 participants.
The verdict
NCT02318277, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.
Interventions
- DRUG MEDI4736
- DRUG INCB024360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2015-01-05 |
| Est. Completion | 2020-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318277
The ClinicalTrials.gov registry entry for NCT02318277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI4736 is the first listed.
NCT02318277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02318277 about?
NCT02318277 is a clinical study titled "A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)". The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.
What is the current status of trial NCT02318277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2015-01-05. Estimated completion is 2020-10-16.
What interventions are being tested in trial NCT02318277?
The interventions under investigation include: MEDI4736 (DRUG), INCB024360 (DRUG).
Who is sponsoring clinical trial NCT02318277?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.